In the phase 2 MASTERPLAN trial, adding SBRT to chemotherapy lowered the rate of cancer returning near the pancreas from 52.0% to 20.2% at one year.
|Articles|November 11, 2021
Drinking Coffee or Tea May Improve Survival After a Breast Cancer Diagnosis
Breast cancer survivors who drink coffee or tea after their breast cancer diagnosis show improved survival in a recent study.
Advertisement
Reassuring news for coffee and tea drinkers! Breast cancer survivors who drink coffee or tea after their breast cancer diagnosis show improved survival in a recent study. Several factors were linked to greater coffee or tea consumption, so this finding must be taken with some caution. However, breast cancer survivors who are regular coffee or tea drinkers may find this research reassuring. Read more in our XRAY review. #helpnothype #BehindtheCancerHeadlines
Advertisement
Related to this article
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient cancer.
Medicare will move ostomy supplies to six national contracts in 2028. Survivors and clinicians say a poor fit can lead to leaks, infection and hospital stays.
An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.
The National Comprehensive Cancer Network released its first patient guideline written for caregivers on Oct. 27, 2026. The free guide covers emotional support, money, legal questions, medical tasks and caregivers' own well-being.
Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were successful, raising questions about how insurers make coverage decisions and what patients can do when their treatment is denied.
Advertisement
Advertisement
Trending on CURE
1
Precision Radiation Cuts 1-Year Pancreatic Cancer Recurrence to 20.2%
2
Medicare to Cut Ostomy Suppliers to 6 Contracts: What Patients Need to Know
3
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
4
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
5